tbuckley/cabot-search huggingface dataset:
High-Dose Targeted Radiation with 131I-Apamistamab Prior to HCT Demonstrated a Dose-Response for Durable Complete Remission in Patients with R/R AML
Authors: Mark R. Litzow, George Chen, Boglarka Gyurkocza, Rajneesh Nath, Stuart Seropian, Hannah Choe, Camille N. Abboud, Nebu Koshy, Ben K. Tomlinson, Sunil Abhyankar, James M. Foran, Sameem Abedin, Zaid Al-Kadhimi, Partow Kebriaei, Mitchell Sabloff, Johnnie J. Orozco, Katarzyna Joanna Jamieson, Margarida Magalhaes-Silverman, Koen Van Besien, Michael W. Schuster, Arjun D. Law, Sebastian A. Mayer, Hillard M. Lazarus, Eugene Leung, Ming-Kai Chen, Mona Natwa, Jennifer Spross, Kate L Li, Norman Nagl, Elaina Haeuber, Madhuri Vusirikala, Akash Nahar, Brenda M. Sandmaier, John Pagel, Sergio A. Giralt, Avinash Desai, Richard L. Wahl, Neeta Pandit-Taskar, Patrik Brodin, Patrick J. Stiff
Journal: Blood (2023)
Removing Transfusion Dependence As a Barrier to Hospice Enrollment (BRUOG-407)
Authors: Pamela Egan, Ari Pelcovits, Caitlyn Krar, Stephen Donnelly, Lila Rubin, Rabin Niroula, John L. Reagan, Dana Guyer, Adam J Olszewski, Thomas W LeBlanc
Journal: Blood (2023)
biomarker Driven Strategies for Targeted Elimination of Hypoxia Adapted Lymphoma Cells
Authors: Pavel Klener, Lenka Daumová, Dmitry Kazantsev, Ladislav Anděra, Jiří Petrák, Alexandra Dolníková, Nardjas Bettazová, Petra Kovaříková, Nicol Renešová, Liliana Tušková, Dana Sovilj, Marek Trněný, Magdalena Klanova, Ondrej Havránek
Journal: Blood (2023)
Safety and Efficacy of Bezuclastinib (CGT9486), a Novel, Highly Selective, Potent KIT D816V Tyrosine Kinase Inhibitor, in Patients with Advanced Systemic Mastocytosis (AdvSM): Results from Part 1 of the Phase 2 Apex Trial
Authors: Pankit Vachhani, Tsewang Tashi, Gary J. Schiller, Stephanie Lee, Miguel Piris Villaespesa, Helena Pomares, Cristina Bulai Livideanu, Jonathan Lambert, Anthony M. Hunter, Tracy I. George, Cristina Papayannidis, Khalid Shoumariyeh, Rita Petroro, Jenna Zhang, Amanda Pilla, Hina Jolin, Rachael Easton, Vinod Pullarkat
Journal: Blood (2023)
A Phase Ib/II Study Evaluating Navitoclax after Failure of Hypomethylating Agent and Venetoclax for Treatment of Relapsed or Refractory High-Risk Myelodysplastic Syndrome
Authors: Gina Keiffer, Sara E. Meyer, Christine Eischen, Ubaldo Martinez Outschoorn, Onder Alpdogan, Adam F. Binder, Pierluigi Porcu, Lindsay Wilde, Margaret Kasner, Neil Palmisiano
Journal: Blood (2023)
Real-World Venetoclax-Obinutuzumab in 232 Treatment Naive CLL Patients: Feasibility and Tolerability
Authors: Alessandra Tedeschi, Andrea Galitzia, Annamaria Frustaci, Caterina Patti, Alessandro Sanna, Lorena Appio, Luana Schiattone, Paolo Sportoletti, Claudia Barate', Beatrice Casadei, Isacco Ferrarini, Amalia Figuera, Caterina Stelitano, Giacomo Loseto, Andrea Visentin, Marta Coscia, Riccardo Moia, Marina Motta, Filomena Russo, Monica Tani, Enrico Capochiani, Angela Ferrari, Massimo Gentile, Roberta Giacchetti, Annamaria Giordano, Vanessa Innao, Marzia Varettoni, Federico Vozzella, Francesca Cibien, Daniela Gottardi, Enrico Lista, Laura Nocilli, Cristina Pasquini, Anna Vanazzi, Elisa Santambrogio, Roberta Murru, Francesca Romana Mauro, Mariano Lucignano, Luca Laurenti
Journal: Blood (2023)
Single-Cell Analysis of Immune Recognition in Chronic Myeloid Leukemia Patients Following Tyrosine Kinase Inhibitor Discontinuation
Authors: Jani Huuhtanen, Shady Adnan-Awad, Jason Theodoropoulos, Sofia Forstén, Rebecca Warfvinge, Olli Dufva, Jonas Bouhlal, Parashar Dhapola, Hanna Duàn, Essi Laajala, Tiina Kasanen, Jay Klievink, Mette Ilander, Taina Jaatinen, Ulla Olsson-Strömberg, Henrik Hjorth-Hansen, Andreas Burchert, Göran Karlsson, Anna Kreutzman, Harri Lähdesmäki, Satu Mustjoki
Journal: Blood (2023)
Outcomes of Patients with Primary Mediastinal B-Cell Lymphoma Refractory or Relapsed after Frontline R-EPOCH Chemotherapy
Authors: Jonathan Bakos, Silvia Escribano Serrat, Yazeed Sawalha, Alison Moskowitz, Anna Crawford, Taylor R. Brooks, Brian T. Hill, Ayo S Falade, Reid W. Merryman, Manali Kamdar, Andrew Ip, Gunjan L. Shah, Arash Velayati, McKenzie Sorrell, James A Davis, Irl Brian Greenwell, Ann LaCasce, Brian Hess
Journal: Blood (2023)
A Collaborative Model for Improving Patient Engagement and Access for Hematopoietic Stem Cell Transplant and Clinical Gene Therapy Trials for Patients with Sickle Cell Disease in the Upper Midwest United States
Authors: Rae Blaylark, Caitlyn Thompson, Roy Kao, Samantha Mallory, Samuel J. Milanovich, Brianna Murphy, Andrea Watson, Asmaa Ferdjallah, Erika Ripken, Alexander A Boucher, Stephanie A. Fritch Lilla, Ashish O. Gupta
Journal: Blood (2023)
Safe and Effective Escalation of Evidence-Based Chemotherapy for Mature B Cell Non-Hodgkin's Lymphoma in a Low Resource Setting
Authors: Anne Akullo, Ruth Namazzi, Peter Wasswa, Casey Lee McAtee, Moureen Nanvuma, Hellen Alamo, Hellen Mugarra Kabawheza, Joseph Lubega, Carl E Allen
Journal: Blood (2023)
Exploring Autologous Hematopoietic Stem Cell Transplantation (HSCT) Utilization and HSCT Refusal Trends in Multiple Myeloma Patients: A Comprehensive Examination of NCDB Data from 2004 to 2020
Authors: Chakra Pani Chaulagain, Ludovic Saba, Kaylee Sarna, Hong Liang, Barbara Geraldine Dominguez, Chieh-Lin Fu
Journal: Blood (2023)
Real-World Bruton Tyrosine Kinase Inhibitor (BTKi) Treatment Patterns Among Patients with Chronic or Small Lymphocytic Leukemia (CLL/SLL) in US Community Oncology Practices
Authors: Jing-Zhou Hou, Simon Blanc, Gregory A Maglinte, Anupama Vasudevan, Anna Rui, Michael Gart, Hoa Pham, Lindsay Aton, Brandon Wang, Rushir Choksi
Journal: Blood (2023)
PHI-101 As a Potent Next-Generation FLT3 Inhibitor, Overcome Resistances in Previously Treated Patients with FLT3-ITD or TKD Acute Myeloid Leukemia: Results of a Phase Ia/Ib Clinical Trial
Authors: Sung-Soo Yoon, Dongyeop Shin, Je-Hwan Lee, Jun Ho Jang, June-Won Cheong, Ho-Jin Shin, Jeong-Ok Lee, Yoo Jin Lee, Joseph Clarey, Gi-Jun Sung, Kyung-Ah Kim, Ky-Youb Nam, Kyu-Tae Kim, June Han, JeongHyeok Yoon, Bao Nguyen, Li Li, Donald Small
Journal: Blood (2023)
Impact of PARP Inhibitor and Platinum Therapy on Clonal Hematopoiesis
Authors: Jeremy T. Baeten, Irenaeus C.C. Chan, Lea Moukarzel, Amber C. Carter, Minal Patel, Konrad H. Stopsack, Paul Pharoah, James Brenton, Bob T Li, Wassim Abida, Alison M. Schram, Karen Cadoo, Britta Weigelt, Carlos Cruchaga, Howard Scher, Ross L Levine, Elli Papaemmanuil, Daniel C. Link, Kelly L. Bolton
Journal: Blood (2023)
Lymphoma-Related Quality of Life (QOL) Is Not Impacted By Initial Treatment Choice in Patients with Marginal Zone Lymphoma (MZL): Results from the Prospective Lymphoma Epidemiology of Outcomes (LEO) Cohort
Authors: Côme Bommier, Mazie Tsang, Brie N. Noble, Carrie Thompson, Carla Casulo, Michelle Hildebrandt, Allison C. Rosenthal, Eric Mou, Urshila Durani, Annalynn M Williams, Kathleen Yost, Melissa C. Larson, Brianna Gysbers, Matthew J. Maurer, Andrew L. Feldman, David L Jaye, Peter Martin, Jonathon B. Cohen, Dai Chihara, Izidore S. Lossos, Christopher Strouse, Brad S. Kahl, Thomas M. Habermann, Christopher R. Flowers, Amylou Constance Dueck, James R. Cerhan
Journal: Blood (2023)
A National Platform and Scoring System Allocates CAR-T Treatment Slots for Multiple Myeloma to Patients with High Likelihood of Complete Remission
Authors: Christoph Driessen, Katharina Baur, Dominik Heim, Sabine Gerull, Christoph Renner, Anne Cairoli, Thomas Pabst, Joerg Halter, Michael Gregor, Nicole Graf, Nino Fejzibegovic, Nathan Wolfensberger, Federico Simonetta, Martin Fehr, Esteban Ciliberti, Rouven Müller, Barbara Jeker
Journal: Blood (2023)
A Longitudinal Study to Assess Hematopoietic Stem Cell and Immune Cell Health in Astronauts Pre-, during, and Post-Mission
Authors: Jessica Pham, Larissa Balaian, Emma E Klacking, Antonio W Ruiz, Jenna Sneifer, Thomas P Frias, Jane Isquith, Shuvro P Nandi, Thomas Whisenant, Elsa Molina, Jana Stoudemire, Pinar Mesci, Ludmil Alexandrov, Catriona Jamieson
Journal: Blood (2023)
Prognostic Impact of Pre-Treatment Cell-Free DNA Concentration in Newly Diagnosed Peripheral T-Cell Lymphomas
Authors: Eugenio Fardella, Giada Zanirato, Martina Magni, Nicole Caldarelli, Annalisa Chiappella, Anna Dodero, Silva Ljevar, Lorella Orsucci, Alessandro Re, Sara Usai, Vittorio Stefoni, Claudia Castellino, Francesca Gaia Rossi, Antonio Pinto, Cristiana Carniti, Paolo Corradini
Journal: Blood (2023)
NGS-Based Stratification Refines the Risk Stratification in T-ALL and Identifies a Very High-Risk Subgroup of Patients
Authors: Mathieu Simonin, Loïc Vasseur, Etienne Lengline, Ludovic Lhermitte, Aurelie Cabannes-Hamy, Marie Balsat, Aline Schmidt, Marie Emilie Dourthe, Aurore Touzart, Carlos Graux, Nathalie Grardel, Jean-Michel Cayuela, Isabelle Arnoux, Virginie Gandemer, Françoise Huguet, Stephane Ducassou, Véronique Lhéritier, Yves Chalandon, Norbert Ifrah, Herve Dombret, Elizabeth A. Macintyre, Arnaud Petit, Philippe Rousselot, Jerome Lambert, André Baruchel, Nicolas Boissel, Vahid Asnafi
Journal: Blood (2023)
The Effects of Mindfulness for Youth (MYmind) versus Group Cognitive Behavioral Therapy in Improving Attention and Reducing Behavioral Problems among Children with Attention-Deficit Hyperactivity Disorder and Their Parents: A Randomized Controlled Trial
Authors: Samuel Yeung Shan Wong, Stanley Kam Chung Chan, Benjamin Hon Kei Yip, Wenyue Wang, Herman Hay Ming Lo, Dexing Zhang, Susan M Bögels
Journal: Psychotherapy and Psychosomatics (2023)

&lt;b&gt;&lt;i&gt;Introduction:&lt;/i&gt;&lt;/b&gt; There is a lack of studies evaluating mindfulness-based interventions for children with attention-deficit hyperactivity disorder (ADHD) compared with an evidence-based control. This randomized controlled trial (RCT) evaluated the effects of mindfulness for youth (MYmind) in improving children’s attention, behavior, and parent-related outcomes versus cognitive behavioral therapy (CBT). &lt;b&gt;&lt;i&gt;Methods:&lt;/i&gt;&lt;/b&gt; A total of 138 families of children with ADHD aged 8–12 years were recruited from the community with 69 randomized to MYmind and 69 to CBT. Participants were assessed at baseline, immediately after intervention, at 3 months and 6 months. The primary outcome was the attention score of the Sky Search subtest of the Test of Everyday Attention for Children (TEA-Ch). Secondary outcomes were child behavior and parent-related assessments. Linear mixed models were used to assess the efficacy of MYmind compared with CBT. &lt;b&gt;&lt;i&gt;Results:&lt;/i&gt;&lt;/b&gt; Both MYmind and CBT significantly improved children’s attention score at 6 months (MYmind: &lt;i&gt;β&lt;/i&gt; = 1.48, &lt;i&gt;p&lt;/i&gt; = 0.013, Cohen’s &lt;i&gt;d&lt;/i&gt; = 0.32; CBT: &lt;i&gt;β&lt;/i&gt; = 1.46, &lt;i&gt;p&lt;/i&gt; = 0.008, &lt;i&gt;d&lt;/i&gt; = 0.27). There were significant within-group improvements in most secondary outcomes. No significant difference was shown for both primary or secondary outcomes between the two arms at any time point. &lt;b&gt;&lt;i&gt;Conclusions:&lt;/i&gt;&lt;/b&gt; Both MYmind and CBT appeared to improve children’s attention and behavior outcomes, although no difference was found between these two interventions. This is the largest RCT so far comparing MYmind and CBT although there was loss of follow-up assessments during the pandemic. Further RCTs adopting a non-inferiority design are needed to validate the results.
Real-World Experience with RTOG 0227 Induction for First Line Therapy of Primary CNS Lymphoma (PCNSL)
Authors: Ramsha Ahmed, Precious Anyanwu, Nirav N. Shah, Mehdi Hamadani, Walter Longo, Sumana Devata, Julie Pruett, Jennifer Connelly, Joseph Bovi, Malika Siker, Christopher Schultz, Timothy S. Fenske
Journal: Blood (2023)
Metabolomic Insights into the Pathogenesis and Prognostic Potential of Adult Acute Lymphoblastic Leukemia
Authors: Junyu Wang, Tuantuan Gui, Tong Yin, Yuting Dai, Jing Qiao, Jianfeng Li, Jie Xu, Yuanfang Liu, Yan Wang, Yun Tan, Bo Jiao, Yongmei Zhu, Zhu Chen, Wenlian Chen, Hai Fang, Jian Hou, Jian-Qing Mi, Jin Wang, Sai-Juan Chen
Journal: Blood (2023)
High-Dose Methotrexate Containing Induction Chemotherapy Followed By Nivolumab Consolidation in Older (≥ 65) Patients with Previously Untreated Primary CNS Lymphoma
Authors: Steven I. Park, Lakshmi Nayak, Danielle Boselli, Raphael E Steiner, Ashley L Sumrall, Nazanin K Majd, Xhevahire Begic, Sarah Norek, Christopher Dittus
Journal: Blood (2023)
Dynamic Changes in Pre- and 3 Months Post-Transplant NGS MRD Status May Predict the Allogeneic Stem Cell Transplant Outcome of Patients with AML
Authors: Hyung C Suh, Amy Einstein, Addi Georgantzis, Phyllis McKiernan, Melissa Baker, Michele S Boonstra, Sukhdeep Kaur, Christina Cho, Scott D Rowley, Michele L. Donato
Journal: Blood (2023)
Preclinical and Clinical Evidence for Erythroid-Stimulating Activity of RVU120 CDK8/19 Inhibitor in AML and MDS
Authors: Noemi Angelosanto, Ewa Lech Marańda, Jan Maciej Zaucha, Camille N. Abboud, Agnieszka Sroka-Porada, Wiktoria Ogrodzińska, Magdalena Kozakowska, Urszula Głowniak-Kwitek, Karolina Bukowska-Strakova, Tomasz Rzymski, Milena Mazan, Urszula Pakulska, Kristina Göller, Ewa Zarzycka, Hendrik Nogai
Journal: Blood (2023)
Clonal Hematopoiesis and Venous Thromboembolism in the UK Biobank
Authors: Becky Zon, Aswin Sekar, Katharine Clapham, Abhishek Niroula, Alexander G. Bick, Christopher James Gibson, Gabriel K. Griffin, Md Mesbah Uddin, Pradeep Natarajan, Benjamin L. Ebert
Journal: Blood (2023)
Real-World Treatment Patterns and Clinical Outcomes in Newly Diagnosed Acute Myeloid Leukemia with and without mIDH1 Treated with Intensive Chemotherapy from an International Real-World Database (REAL-IDH)
Authors: Joshua F. Zeidner, Priyanka Mehta, Benyam Muluneh, Sarah Bertoli, Pierre-Yves Dumas, Arnaud Pigneux, Cédric Fernandez, Hélène Derrien, Christian Recher
Journal: Blood (2023)
Treatments and Outcomes of Lymphoma-Associated Hyperinflammation- a Report from the HLH in Adults Working Group for the Histiocyte Society
Authors: Adi Zoref-Lorenz, Swami P. Iyer, Jun Murakami, Liron Hofstetter, Rishab Prakash, Shiri Weinstein, Joanne Yacobovich, Shai Izraeli, Sarah Nikiforow, Ronit Gurion, Inbar Cohen, Pia Raanani, Arnon Nagler, Nancy Berliner, Martin H. Ellis, Gilad Itchaki, Michael B. Jordan, David Pottinger, Jerome Razanamahery, Zhao Wang, Gaurav Goyal
Journal: Blood (2023)
Randomized Controlled Double Blind Feasibility Trial of Tadalafil with Hydroxyurea Versus Hydroxyurea with Placebo for Secondary Prevention of Recurrent Priapism in Men with Sickle Cell Anemia: Pin Trial Final Results
Authors: Ibrahim Musa Idris, Aminu Abba Yusuf, Ismail Ismail, Awwal Musa Borodo, Kabiru Musangedu, Tukur Aliyu, Datti Alfa, Mustapha Shuaiabu Hikima, Mohammad Suwaid, Shehu Kana, Sani Aji, Aisha Kuliya Gwarzo, Kabiru Bello Muhammad, Jamil Aliyu Galadanci, Rukayya Alkassim, Nafiu Hussaini, Mark Rodeghier, Arthur Burnett, Michael R. DeBaun
Journal: Blood (2023)
Cerebral Oxygen Metabolism Improves Following Hematopoietic Cell Transplantation in Children with Sickle Cell Disease
Authors: Chih-Chiang Chang, Matthew A. Scoggins, Ping Zou, Sydney Somogyi, Soniya Pinto, Kathleen Helton, Jane S Hankins, Brandon M Triplett, Akshay Sharma, Ranganatha Sitaram
Journal: Blood (2023)
The Actin Bundling Protein L-Plastin Mediates Platelet Force Generation and Thrombosis
Authors: Seema Bhatlekar, Shancy Jacob, Marina Tistao, Molly Y Mollica, Nicole Rhoads, Lili Chen, Bhanu Kanth Manne, Darian Murray, Siqi Guo, Sharon Celeste Morley, Jesse W Rowley, Matthew T. Rondina, Raymond Adili, Jose A. Lopez, Li Guo
Journal: Blood (2023)
The Optimal Threshold for Hemoglobin S Percent Level While Performing Regular Blood Transfusion Therapy to Prevent Severe Vaso-Occlusive Pain Events in Children with Sickle Cell Anemia: A Secondary Data Analysis of Participants in the SIT Trial
Authors: Jose A. Mejias, Alejandro R. Gonzalez-Barreto, Mark Rodeghier, Michael R. DeBaun
Journal: Blood (2023)
Metformin-Induced Ferroptosis Is a Therapeutic Vulnerability in <i>IDH2</i>-Mutant AML Linked to Metabolic Rewiring Towards Fatty Acid Oxidation
Authors: Dominique Sternadt, Diego Pereira-Martins, Douglas RA Silveira, Isabel Weinhaeuser, Ming Yang, Prodromos Chatzikyriakou, Pilar Casares Alaez, Emanuele Ammatuna, Lieve Oudejans, Gerwin A. Huls, Christian Frezza, Lynn Quek, Jan Jacob Schuringa
Journal: Blood (2023)
One-Year Safety and Efficacy of Mitapivat in Sickle Cell Disease: Follow-up Results of a Phase 2, Open-Label Study
Authors: Myrthe J. van Dijk, Minke A.E. Rab, Brigitte A. van Oirschot, Jennifer Bos, Cleo Derichs, Anita W. Rijneveld, Marjon H. Cnossen, Erfan Nur, Bart J. Biemond, Marije Bartels, Judith J.M. Jans, Wouter W. van Solinge, Roger E.G. Schutgens, Richard van Wijk, Eduard J. Van Beers
Journal: Blood (2023)
A Pan-Cancer Single-Cell Transcriptomic Atlas of Natural Killer (NK) Cells Reveals Intrinsic and Extrinsic Mediators of NK Cell Anti-Tumor Functions
Authors: John R Lozada, Atef Ali, Abderrahman Day, Jacob A Myers, Ella Boytim, Hannah Bergom, Nicholas Zorko, Martin Felices, Jeffrey S Miller, Justin Hwang, Frank Cichocki
Journal: Blood (2023)
Somatic and Germline Cohesin Genes Alterations in Pediatric Acute Lymphoblastic Leukemia
Authors: Stefano Rebellato, Claudia Saitta, Laura Rachele Bettini, Daniela Silvestri, Orietta Spinelli, Agata Pastorczak, Danielle Brandes, Ute Fischer, Arndt Borkhardt, Sabine Strehl, Luca Lo Nigro, Barbara Buldini, Julia Hauer, Franziska Auer, Lennart Kester, Roland P. Kuiper, Luciana Vinti, Franco Locatelli, Andrea Biondi, Grazia Fazio, Giovanni Cazzaniga
Journal: Blood (2023)
Inflammation Mediated By TNFα Disrupts the Autophagic Flux and Oxidative Phosphorylation of Megakaryocytes and Platelets through the Downregulation of STX17
Authors: Guadalupe Rojas-Sanchez, Jorge Calzada-Martinez, Brandon McMahon, Orlando Esparza, Giovanny Hernandez, Dennis L Le, Eric Wartchow, Tzu Phang, Travis Nemkov, Angelo D'Alessandro, Paola Maycotte, Andrew Thorburn, Jose A. Lopez, Pavel Davizon-Castillo
Journal: Blood (2023)
A Phase II Study to Evaluate the Safety and Efficacy of Defibrotide and Changes in Plasma Biomarkers in Sickle Cell Disease-Related Acute Chest Syndrome (IND 127812)
Authors: Edo Schaefer, Morgan Anderson-Crannage, Jessica Hochberg, Temima Kanarfogel, Yiouli Panayiota Ktena, John Herrick, Emily Thatcher, Qiuhu Shi, Bruno Hochberg, Yaya Chu, Sankaran Krishnan, Erin Morris, Sandra Fabricatore, John DuFresne, Kenneth R. Cooke, Mitchell S. Cairo
Journal: Blood (2023)
Real-World Outcomes of Newly Diagnosed Multiple Myeloma (NDMM) Patients Treated before the Anti-CD38 Antibodies Era in France, the Emmy Cohort 2017 to 2020
Authors: Laure Vincent, Olivier Decaux, Aurore Perrot, Bruno Royer, Thomas Chalopin, Arthur Bobin, Margaret Macro, Denis Caillot, Lionel Karlin, Caroline Jacquet, Cécile Sonntag, Mohamad Mohty, Laurent Frenzel, Arnaud Jaccard, Laurence Sanhes, Driss Chaoui, Nathalie Texier, Chanaz Louni, Zakaria Maarouf, Herve Avet Loiseau, Cyrille Hulin, Karim Belhadj Merzoug
Journal: Blood (2023)
Fertility and Pregnancy in Patients with Congenital Neutropenia: Experience of the French Severe Chronic Neutropenia Registry in 565 Patients Above Age of 15 Years
Authors: Aurelia Alimi, Evrard Nika, Blandine Beaupain, Claire Fieschi, Flore Sicre De Fontbrune, Nathalie Aladjidi, Despina Moshous, Aline Moignet.Autrel, Coralie Mallebranche, Martin Biosse Duplan, Christine Bellanne-Chantelot, Jean Donadieu
Journal: Blood (2023)
Sickle Cell Health Awareness, Perspectives, and Experiences (SHAPE) Survey: Findings on the Burden of Sickle Cell Disease and Impact on the Quality of Life of Patients and Caregivers in Gulf Cooperation Council Countries
Authors: Wasil Jastaniah, Regina Hartfield, John James, Biba Tinga, Elvie Ingoli, Mariane de Montalembert, Fernando F. Costa, Alan Randall Anderson, Joachim B. Kunz, Isaac Odame, Belinda Lartey, Baba P.D. Inusa
Journal: Blood (2023)
Pharmacokinetics, Pharmacodynamics, Safety, and Efficacy of Crizanlizumab in Patients with Sickle Cell Disease: Final Interim Analysis Results from the Phase 2 Solace-Adults Study
Authors: Julie Kanter, Sarah Mennito, Santosh M Nair, Deepa Manwani, Abdullah Kutlar, Nirmish Shah, Deborah Keefe, Hariprasad Madhamshetty, Evgeniya Reshetnyak, Anisha E Mendonza, Darla K. Liles
Journal: Blood (2023)
Gain1q in Myeloma Randomized Clinical Trials- How Is It Reported and How Does It Impact Outcomes: A Systematic Review
Authors: Karun Neupane, Gliceida Galarza Fortuna, Riyasha Dahal, Timothy M Schmidt, Rafael Fonseca, Doug Sborov, Meera Mohan, Hira Mian, Rajshekhar Chakraborty, Ghulam Rehman Mohyuddin
Journal: Blood (2023)
Dose Escalation of ISB 1342, a Novel CD38xCD3 Bispecific Antibody, in Patients with Relapsed / Refractory Multiple Myeloma (RRMM)
Authors: Prashant Kapoor, Don A. Stevens, Xavier Leleu, Karim Belhadj Merzoug, Lionel Karlin, Salomon Manier, Thomas Chalopin, Cyrille Hulin, Aurore Perrot, Jésus G Berdeja, Cristiana Costa Chase, Cyrille Touzeau, Philippe Moreau, Sanjay Mohan, Alexander Lesokhin, Carol Huff, David H. Vesole, Joshua Richter, Jeffrey Matous, Eileen Wolff, Tejas Shah, Jeppe Koch-Olsen, Andrew Garton, Vinu Menon, Sunitha Gn, Mario Perro, Eugene Zhukovsky, Cyril Konto, Lida Pacaud, Mohamad Mohty
Journal: Blood (2023)
Study Assessing the All4Cure Health Technology Intervention on Patient Activation in Multiple Myeloma
Authors: Mehdi M. Moezi, Mohamad Kanaan, Patrick M. Travis, Tara Graff, Cheng Zheng, Jessa Dunivan, Tiffany Wood, Sophia Essiet, Jessica Faucheaux, Brian Decker, Jennifer Wren, Leena Chhun, Jayne Piboonvaranggoon, Mark Walker, Trudy Buckingham, Joseph Guidi, Shannon Altimari, C. Anthony Blau
Journal: Blood (2023)
Protective Role of Oxaliplatin Among Platinum-Based Therapies in the Development of Therapy-Related Myeloid Neoplasms
Authors: Jeremy S Connors, Linda Zhang, Koji Sasaki, Courtney D. DiNardo, Nicholas J. Short, Naval Daver, Gautam Borthakur, Tapan M. Kadia, Hagop Kantarjian, Elias Jabbour, Margaret A Goodell, Guillermo Garcia-Manero, Koichi Takahashi
Journal: Blood (2023)
Integrated Molecular Landscape of Lesions in Cereblon and Its Pathway in Myeloma Patients: Insights into Mechanisms of Relapse from IMiD-Based Treatments
Authors: Lisa B Leypoldt, Torsten Steinbrunn, Phaik Ju Teoh, Ricardo De Matos Simoes, Ryosuke Shirasaki, Constantine S Mitsiades
Journal: Blood (2023)
Updated Safety and Efficacy Results of Abbv-383, a BCMA x CD3 Bispecific T-Cell Redirecting Antibody, in a First-in-Human Phase 1 Study in Patients with Relapsed/Refractory Multiple Myeloma
Authors: Ravi Vij, Shaji Kunnathu Kumar, Anita D'Souza, John T Mckay, Peter M. Voorhees, Alfred Chung, Sascha Alexander Tuchman, Neha Korde, Katja Weisel, Raphael Teipel, Orlando Bueno, Zhongling Feng, Tanya S Rosenberg, Rajvineeth Kumar Pothacamury, Akshanth R Polepally, Shane Lee, Ziyi Jin, Jeremy A Ross, Aarif Ahsan, Chetasi Talati, Cesar Rodriguez
Journal: Blood (2023)
The Ingenious Multiple Efficacies of the Integrated Gene Fragment of Torque Teno Mini Virus in Orchestrating Promyelocytic Leukemogenesis Via Hijacking Rara
Authors: Xiaosu Zhou, Xue Chen, Jiaqi Chen, Panxiang Cao, Fang Wang, Yang Zhang, Xiaoli Ma, Jiancheng Fang, Linya Wang, Lijun Wen, Ping Wu, Ruijie Tang, Wanting He, Siyuan Liu, David Jin, Xian Zhang, Suning Chen, Huyong Zheng, Peihua Lu, Hongxing Liu
Journal: Blood (2023)
Multi-Omic Insights into the Mutational Landscape and Dysregulated Transcriptional Programs of Autoimmune B-Cells in Systemic Lupus Erythematosus
Authors: Arghavan Ashouri, Pathum Kossinna, Xuyao Li, Jahin Kabir, Jianfan Nie, Artem Kushnirenko, Ilham Abbasi, Leandro Venturutti, Zahi Touma, Federico Gaiti
Journal: Blood (2023)
Over 4 Years of Safety and Efficacy with Voxelotor Treatment for Patients with Sickle Cell Disease: Updated Results from an Open-Label Extension of the Phase 3 HOPE Trial
Authors: Maureen Okam Achebe, Hoda MA Hassab, Salam Al-Kindi, Clark Brown, Paul Telfer, Bart J. Biemond, Thokozeni Lipato, Mark Davis, Sarah Gray, Victor R. Gordeuk
Journal: Blood (2023)
Asciminib Is Effective Against <i>ABL1</i> Gene Fusions in Acute Lymphoblastic Leukemia but Only When the <i>ABL1</i> SH3 Domain Is Present
Authors: Laura N Eadie, Caitlin E Schutz, Elyse C Page, Tace S Conlin, Susan L Heatley, Elias Lagonik, Jacqueline A Rehn, David T Yeung, Timothy P Hughes, Deborah L White
Journal: Blood (2023)